U.S. FDA Grants Fast Track Designation to Novavax’ RSV F-Protein Nanoparticle Vaccine for Protection of Infants Via Maternal Immunization

November 20, 2014 Novavax, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Novavax’ RSV F-Protein nanoparticle vaccine candidate (RSV F vaccine) for protection of infants via maternal immunization. “The FDA’s granting of Fast Track designation …

Novavax Announces Positive Top-Line Data from Dose-Confirmatory Phase 2 Clinical Trial of its RSV Vaccine Candidate in Women of Childbearing Age

Vaccine candidate was well-tolerated with no vaccine-related serious adverse events Highest immune responses observed with a single dose of vaccine combined with aluminum phosphate adjuvant Women with the lowest baseline levels of RSV neutralizing antibodies had the largest increases following immunization, consistent with prior data Palivizumab-like antibodies exceeded levels observed in previous trials  High levels of antibodies developed within 14 days after …

Novavax Appoints John J. Trizzino as Senior Vice President, Commercial Operations

Novavax Appoints John J. Trizzino as Senior Vice President, Commercial Operations March 10, 2014 Novavax, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of John J. Trizzino to the position of Senior Vice President, Commercial Operations, effective March 10, 2014. Mr. Trizzino will be responsible for …

Researchers develop method to deliver vaccines directly to lymph nodes

Researchers at the University of Illinois at Chicago have developed a system for precisely delivering anti-inflammatory drugs to immune cells gone out of control, while sparing their well-behaved counterparts. Their findings were published online Feb. 23 in Nature Nanotechnology. The system uses nanoparticles made of tiny bits of protein designed to bind to unique receptors found only on neutrophils, a type …

Durable nanoparticle vaccine improves mucosal immunity

Many bacterial and viruses infect humans though mucosal surfaces such as the lungs, but often these surfaces clear the vaccine away before it can trigger the desired immune response. Therefore, scientists have been working towards a vaccine that will stick around at the mucosal surfaces for a little longer. Now researchers at the Massachusetts Institute of Technology (MIT) say they …

Golden opportunity: Nanotech RSV vaccine based on gold particles

Researchers writing in Nanotechnology have developed a novel vaccination method to combat the respiratory syncytial virus (RSV) using tiny gold nanorods to mimic the virus. The nanorod constructs, which are just 21 nanometres wide and 57 nanometres long, are almost exactly the same shape and size as the RSV virus and are coated in the virus' fusion (F) protein. The …

Next Generation Immunotherapies

Peter Keller, Vice President Business Development, Selecta Biosciences joined us at the World Vaccine Congress Lyon 2012 to present on Synthetic Vaccine Particle technology. This technology has been created to help maximise the potential for the use of nanoparticles in vaccines. Nanoparticles have the optimal size for recognition by the immune system: The human immune system has evolved to recognize …